These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32368692)

  • 1. Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial.
    Garcia-Lunar I; Blanco I; Fernández-Friera L; Prat-Gonzàlez S; Jordà P; Sánchez J; Pereda D; Pujadas S; Rivas M; Solé-Gonzalez E; Vázquez J; Blázquez Z; García-Picart J; Caravaca P; Escalera N; Garcia-Pavia P; Delgado J; Segovia-Cubero J; Fuster V; Roig E; Barberá JA; Ibanez B; García-Álvarez A
    JACC Basic Transl Sci; 2020 Apr; 5(4):317-327. PubMed ID: 32368692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial.
    García-Álvarez A; Blanco I; García-Lunar I; Jordà P; Rodriguez-Arias JJ; Fernández-Friera L; Zegri I; Nuche J; Gomez-Bueno M; Prat S; Pujadas S; Sole-Gonzalez E; Garcia-Cossio MD; Rivas M; Torrecilla E; Pereda D; Sanchez J; García-Pavía P; Segovia-Cubero J; Delgado JF; Mirabet S; Fuster V; Barberá JA; Ibañez B;
    Eur J Heart Fail; 2023 Mar; 25(3):373-385. PubMed ID: 36404400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component.
    Caravita S; Faini A; Carolino D'Araujo S; Dewachter C; Chomette L; Bondue A; Naeije R; Parati G; Vachiéry JL
    PLoS One; 2018; 13(6):e0199164. PubMed ID: 29920539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial.
    Bundgaard H; Axelsson Raja A; Iversen K; Valeur N; Tønder N; Schou M; Christensen AH; Bruun NE; Søholm H; Ghanizada M; Fry NAS; Hamilton EJ; Boesgaard S; Møller MB; Wolsk E; Rossing K; Køber L; Rasmussen HH; Vissing CR
    Circ Heart Fail; 2022 Jul; 15(7):e009120. PubMed ID: 35758031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.
    García-Álvarez A; Pereda D; García-Lunar I; Sanz-Rosa D; Fernández-Jiménez R; García-Prieto J; Nuño-Ayala M; Sierra F; Santiago E; Sandoval E; Campelos P; Agüero J; Pizarro G; Peinado VI; Fernández-Friera L; García-Ruiz JM; Barberá JA; Castellá M; Sabaté M; Fuster V; Ibañez B
    Basic Res Cardiol; 2016 Jul; 111(4):49. PubMed ID: 27328822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications.
    Omote K; Sorimachi H; Obokata M; Reddy YNV; Verbrugge FH; Omar M; DuBrock HM; Redfield MM; Borlaug BA
    Eur Heart J; 2022 Sep; 43(36):3417-3431. PubMed ID: 35796488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of remote haemodynamic-guided heart failure management in patients with different subtypes of pulmonary hypertension: insights from the MEMS-HF study.
    Assmus B; Angermann CE; Alkhlout B; Asselbergs FW; Schnupp S; Brugts JJ; Nordbeck P; Zhou Q; Brett ME; Ginn G; Adamson PB; Böhm M; Rosenkranz S
    Eur J Heart Fail; 2022 Dec; 24(12):2320-2330. PubMed ID: 36054647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary hypertension due to left heart diseases.
    Vachiéry JL; Adir Y; Barberà JA; Champion H; Coghlan JG; Cottin V; De Marco T; Galiè N; Ghio S; Gibbs JS; Martinez F; Semigran M; Simonneau G; Wells A; Seeger W
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D100-8. PubMed ID: 24355634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary hypertension and ventilation during exercise: Role of the pre-capillary component.
    Caravita S; Faini A; Deboeck G; Bondue A; Naeije R; Parati G; Vachiéry JL
    J Heart Lung Transplant; 2017 Jul; 36(7):754-762. PubMed ID: 28131663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement.
    Weber L; Rickli H; Haager PK; Joerg L; Weilenmann D; Brenner R; Taramasso M; Baier P; Maisano F; Maeder MT
    Eur J Heart Fail; 2019 Feb; 21(2):172-181. PubMed ID: 30328215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Diagnostic Challenge of Group 2 Pulmonary Hypertension.
    Naeije R; D'Alto M
    Prog Cardiovasc Dis; 2016; 59(1):22-9. PubMed ID: 27195751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrected MRI Pulmonary Transit Time for Identification of Combined Precapillary and Postcapillary Pulmonary Hypertension in Patients With Left Heart Disease.
    Gong C; Guo X; Wan K; Chen C; Chen X; Guo J; He J; Yin L; Wen B; Pu S; Chen Y
    J Magn Reson Imaging; 2023 May; 57(5):1518-1528. PubMed ID: 37021578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein A1 is associated with pulmonary vascular resistance and adverse clinical outcomes in patients with pulmonary hypertension secondary to heart failure.
    Yu W; Dujiang X; Yi W; Guanwen D; Mengyu Z; Chang P; Aikai Z; Juan Z; Linlin Z; Hang Z
    Pulm Circ; 2022 Jul; 12(3):e12096. PubMed ID: 35911182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
    Kramer T; Dumitrescu D; Gerhardt F; Orlova K; Ten Freyhaus H; Hellmich M; Baldus S; Rosenkranz S
    Int J Cardiol; 2019 May; 283():152-158. PubMed ID: 30777406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary hypertension associated with left heart disease (group 2)].
    Schmidt KH; Bikou O; Blindt R; Bruch L; Felgendreher R; Hohenforst-Schmidt W; Holt S; Ladage D; Pfeuffer-Jovic E; Rieth A; Schmeisser A; Schnitzler K; Stadler S; Steringer-Mascherbauer R; Yogeswaran A; Kuebler WM
    Pneumologie; 2023 Nov; 77(11):926-936. PubMed ID: 37963482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review.
    Kido K; Coons JC
    Pharmacotherapy; 2019 Sep; 39(9):929-945. PubMed ID: 31349390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Functional characterization of patients with isolated post-capillary or combined post-capillary and pre-capillary pulmonary hypertension].
    Held M; Weiner S; Walthelm J; Joa F; Hoffmann J; Güder G; Pfeuffer-Jovic E
    Dtsch Med Wochenschr; 2021 Oct; 146(21):e88-e94. PubMed ID: 34670324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches.
    Rosenkranz S; Kramer T; Gerhardt F; Opitz C; Olsson KM; Hoeper MM
    Herz; 2019 Sep; 44(6):483-490. PubMed ID: 31317203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Functional characterization of patients with isolated post-capillary or combined post-capillary and pre-capillary pulmonary hypertension].
    Held M; Weiner S; Walthelm J; Joa F; Hoffmann J; Güder G; Pfeuffer-Jovic E
    Pneumologie; 2022 Oct; 76(10):689-696. PubMed ID: 36257308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction.
    Dixon DD; Trivedi A; Shah SJ
    Heart Fail Rev; 2016 May; 21(3):285-97. PubMed ID: 26714826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.